CXXC5 is a member of a small subset of proteins containing CXXC-type zinc-finger domain. Here, we show that CXXC5 is a transcription factor activating Flk-1, a receptor for vascular endothelial growth factor. CXXC5 and Flk-1 were accmulated in nucli and membrane of mouse embryonic stem cells (mESCs), respectively, during their endothelial differentiation. CXXC5 overexpression induced Flk-1 transcription in both endothelium-differentiated mESCs and human umbilical vein endothelial cells (HUVECs). 
ple, BMP2 and BMP4 mediate the endothelial differentiation of ESCs (10 -12) and regulate endothelial cellular functions. Both noggin and chordin, the antagonists of BMP2 and BMP4, inhibit BMP-mediated angiogenesis during murine development (12) . In zebrafish embryos, BMP signaling plays a critical role in specific vessel formation; BMP2 and BMP receptor (BMPR1/2) are specifically involved in the formation of the caudal vein plexus (CVP) but not the formation of intersegmental arteries (ISAs) during early vascular development (13) . BMP4 induces the differentiation of ESCs into Flk-1-positive cells in serum-free conditions and is involved in the proliferation and migration of endothelial cells via activation of Flk-1 (8, 9) . Injection of human BMP4 mRNA induced Flk-1 expression in zebra fish embryos (7) . These studies implicate the relationship between BMP4 and Flk-1; however, detailed mechanisms and mediators for the Flk-1 regulation by BMP signaling have not been elucidated.
CXXC5, a zinc-finger family protein evolutionarily conserved among vertebrates (14) , is a newly identified target of BMP signaling (15) . CXXC5 is a transcriptional target of Wilms tumor 1 (WT1) and is also a negative regulator of the Wnt/␤-catenin signaling pathway (16) . In addition, CXXC5 localizes in the cytoplasm and interacts with Dishevelled in neural progenitor cells (15) . However, CXXC5 has several motifs in the C-terminal region, such as putative nuclear localization signals (NLSs) and CXXC domains that could be involved in DNA interactions, indicating its potential role as a nuclear DNA-binding factor (17) (18) (19) (20) (21) . In promyelocytic leukemia cells, CXXC5 was observed in the nucleus (20) , and a recent study identifies CXXC5 as a hypoxia-induced transcription factor of cytochrome c oxidase subunit 4-2 (22) . In this study, we characterized CXXC5 as a BMP-induced nuclear transcription factor activating Flk-1 and further identified its roles in endothelial cell differentiation, migration, and vessel formation. High nuclear expression of CXXC5 during endothelial differentiation in mouse ESCs (mESCs) indicated that CXXC5 acts as a transcription factor mediating endothelial differentiation. Furthermore, in both endothelial-differentiated mESCs and human umbilical vein endothelial cells (HUVECs), overexpression and knockdown of CXXC5 resulted in an increase and decrease, respectively, in the expression of Flk-1. In vitro DNA-binding assay and experiments using a putative DNA-binding domain-deleted CXXC5 mutant confirmed the role of CXXC5 as a transcription factor driving Flk-1 expression. We identified BMP signaling as an upstream pathway for CXXC5 transcriptional regulation. BMP4 stimulated Flk-1 induction and cell motility in endothelial cells, whereas the BMP-induced Flk-1 expression and cell mobility were abolished by CXXC5 knockdown. CXXC5 was expressed in the posterior cardinal vein (PCV) region of zebrafish embryos in early developmental stages, and CXXC5 knockdown resulted in a specific defect of CVP formation, which is known as a BMP-signaling-specific vessel formation. Finally, a role of CXXC5 in the BMP-induced angiogenesis was revealed by Matrigel plug assay in CXXC5 Ϫ/Ϫ mice. These results indicate CXXC5 to be a BMP-signaling-specific mediator for Flk-1 regulation and in vitro and in vivo vessel formation.
MATERIALS AND METHODS
Cell culture, transfection, and reporter analysis mESCs and HUVECs were cultured as described in a previous study (23) .The mESCs were maintained on mitomycin C (Sigma, St. Louis, MO, USA)-treated mouse embryonic fibroblast (MEF) feeder cells in knockout Dulbecco's modified Eagle medium (Gibco, Grand Island, NY, USA) supplemented with 15% fetal bovine serum (FBS; Gibco), 1000 U/ml of leukemia inhibitory factor (Esgro; Chemicon International, Temecula, CA, USA), MEM nonessential amino acids (Gibco), and 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol (Gibco). For the undifferentiation condition, the mESCs were transferred onto 0.1% gelatin (Sigma)-coated dishes. For endothelial differentiation, mESCs were cultured on mouse collagen IV (BD Biosciences, San Jose, CA, USA)-coated dishes in ␣-MEM (Gibco) containing 15% FBS and 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol for 4 d. For transient transfection, mESCs were grown for 1 d, transfected with the required plasmids using the Lipofectamine Plus reagent, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA), and then further cultured for 3 d in undifferentiation or differentiation medium and harvested. For indicated cases, mESCs and HUVECs were treated with Wnt3a, BMP4, noggin (R&D Systems, Minneapolis, MN, USA), dorsomorphin (DM; Sigma), or transforming growth factor ␤ (TGF-␤; Peprotech, Rocky Hill, NJ, USA) after transfection. For reporter analysis, cells were harvested, rinsed in phosphate-buffered saline (PBS; Gibco), and resuspended in reporter lysis buffer (Promega, Madison, WI, USA) for the luciferase assay. Luciferase activities were measured using a FLUOstar Optima platereader (BMG Lab Technologies, Offenburg, Germany) and normalized using ␤-galactosidase activity as an internal control (24) .
RT-PCR
Total RNA was extracted from feeder-independent mESCs and HUVECs using the TRIzol reagent (Invitrogen). Reverse transcription was performed with M-MLV reverse transcriptase (Invitrogen). PCR reactions were performed with TaqDNA polymerase (Cosmo Genetech, Seoul, Korea) at 94°C for 5 min followed by 25-35 cycles of 94°C for 30 s, 55-58°C for 30 s, and 72°C for 1 min in a System 2700 (Applied Biosystems, Foster City, CA, USA). For mRNA detections, the following pairs of primers were used: mouse Flk-1, forward 5=-tgtactgagagatgg-gaacc-3= and reverse 5=-gtgttgctccttctttcaac-3=; human Flk-1, forward 5=-tgatcggaaatgacactggagcct-3= and reverse 5=-ttcttggtcatcagcccactggat-3=;, mouse Tie-2, forward 5=-tctgtggagtcagcttgctccttt-3= and reverse 5=-tgagggatg-tttcggcatcagaca-3=; mouse CyclinD1, forward 5= -tgctgcaaatggaactgcttctgg-3= and reverse 5=-taccatggagggtgggttggaaat-3=; mouse c-Myc, forward 5=-tggtgtctgtggagaagaggcaaa-3= and reverse 5=-ttggcagctggatagtccttcctt-3=; mouse HPRT, forward 5=-cctgctggattacattaaagcact-3= and reverse 5=-gtcaagggcatat-ccaacaacaaa-3=; mouse CXXC5, forward 5=-agcagtttgcacagtccacagaga-3= and reverse 5=-tggccagtctttcggttcctacaa-3=; human CXXC5, forward 5=-atggcggtg-gacaaaagcaac-3= and reverse 5=-tcactgaaaccaccggaaggc-3=; mouse CXXC4, forward 5=-ttcctctccaccttatcccc-3= and reverse 5=-tctagcgaagtgccaggttt-3=; hu-man CXXC4, forward 5=-ttcctctccaccttatcccc-3= and reverse 5=-tctagcgaag-tcccaggttt-3=; and human GAPDH, forward 5=-aaggtcggagtcaacggatttggt-3= and reverse 5=-agtgatggcatggactgtggtcat-3=). All primers were synthesized by Bioneer (Seoul, South Korea).
Western blot analysis
mESCs and HUVECs were grown and treated with Wnt3a, BMP4, noggin, or DM after transfection. After being cultured, cells were harvested and scraped into a microcentrifuge tube. Whole-cell lysates or fractionated lysates were subjected to Western blot analysis as described previously (23) . For cell fractionation, the cells were harvested by centrifugation (450 g, 5 min), incubated on ice for 15 min in lysis buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 10m M KCl; 0.01 M DTT; and protease inhibitors) for swelling, and subsequently was mixed with 10% IGEPAL CA-630 (Sigma). This cell lysate was centrifuged (10,000 g, 30 s), and the supernatant was saved as cytoplasmic fraction. The resulting cell pellet was resuspended in extract buffer (20 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 0.42 M NaCl; 0.2 mM EDTA; 25% glycerol; 0.01 M DTT; and protease inhibitors) and vortex mixed for 15ϳ30 min. This extract was centrifuged (20,000 g, 5 min), and the supernatant was saved as the nuclear fraction. Anti-Oct-4, anti-Flk-1, anti-␤-catenin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Lamin A/C (Cell Signaling, Beverly, MA), anti-CXXC5, and anti-␤-actin (Abcam, Cambridge, UK) primary antibodies were used, followed by incubation with horseradish peroxidase-conjugated anti-rabbit (Bio-Rad Laboratories, Hercules, CA, USA) or anti-mouse (Cell Signaling) IgG secondary antibodies. Protein bands were visualized with enhanced chemiluminescence (ECL; Amersham Bioscience, Piscataway, NJ, USA) using a luminescent image analyzer (LAS-3000; Fujifilm, Tokyo, Japan).
Plasmids
A 0.9-kb human CXXC5 cDNA fragment was obtained by PCR using a pair of primers, forward 5=-GCTCTAGACTATGTC-GAGCCTCGGCGGT-3= and reverse 5=-CGCGGATCCTCACT-GAAAC-CACCGGAAGGC-3=, from a CXXC5 cDNA clone [GenBank accession no. BC017439; American Type Culture Collection (ATCC), Manassas, VA, USA]. The product was cut with XbaI and BamHI and subcloned into the identical site of the pcDNA3.1/myc His(Ϫ) A vector (Invitrogen; Myc-CXXC5-pcDNA3.1). The pGEX4T1-CXXC5 construct for GST-CXXC5 fusion protein production was generated by inserting an EcoRI-and SalI-restricted 0.9-kb cDNA fragment of the CXXC5 cDNA clone into same sites of pGEX4T1 (Amersham Bioscience). For CXXC5 (⌬250 -322), a pair of primers, forward 5=-GCTCTAGACTATGTCGAGCCTCG-GCGGT-3= and reverse 5=-CGC GGATCCCAGCTCTCCCTG-CATGGG-3=, was used, and for CXXC5 (⌬1-249), a pair of primers, forward 5=-GCTCTAGACCATGCAGGGAGAGCTG-3= and reverse 5=-CGCGGATCCTCACTGAAACCACCGGAAGGC-3=, was used. By PCR using these primers, 0.9-, 0.7-, and 0.2-kb CXXC5 mutant fragments were obtained, respectively. All products were cut with XbaI and BamHI and subcloned into identical sites of the pcDNA3.1/myc His(Ϫ) A, and named Myc-CXXC5 (⌬250 -322)-pcDNA3.1 and Myc-CXXC5 (⌬1-249)-pcDNA3.1, respectively. CXXC5 point mutants (C263/266R, C275/278R) were generated by PCR-based mutagenesis using the following primers: C263/266R, forward 5=-CGGAAACGCCGCGGCAT-GCGCGCGCC-CTGC-3= and reverse 5=-GCAGGGCGCGCG-CATGCCGCGGCGTTTCCG-3=; C275/278R, forward 5=-CGCATCAACCGCGAGCAGCGCAGCAGTTGT-3= and reverse 5=-ACAACTGCTGCGCTG-CTCGCGGTTGATGCG. All primers were synthesized by Bioneer. All constructs and mutations were confirmed by nucleotide sequencing. Flk-1-Luc-pGL3 (25) was obtained from Dr. L. Zeng (University of London, London, UK). An shRNA plasmid targeting CXXC5 (TRCN0000219529) and its backbone plasmid (pLKO.1-puro) were purchased from Sigma. A gene cassette containing internal ribosome entry site and green fluorescence protein coding region was inserted into these 2 plasmids to generate CXXC5 shRNA vetor and empty shRNA vector, respectively.
Generation of anti-CXXC5 antibody
GST-CXXC5 fusion proteins were overexpressed in Escherichia coli BL21(DE3) pLysS cells and transformed with pGEX4T1-CXXC5, and GST-CXXC5 was purified as described previously (26) . An anti-CXXC5 antiserum was generated by immunizing a New Zealand White rabbit initially with 1 mg of the purified GST-CXXC5 mixed with 1 ml Freund's complete adjuvant and then subsequently at 2 wk intervals (2nd and 3rd). A week after the 3rd injection, serum was obtained by euthanizing the animal. The anti-CXXC5 antibody was purified from the antiserum as described previously (27) .
siRNA and treatment
siRNAs for mouse CXXC5 (NM_133687; 5=-ACAUCUCCACGUC-CCUAGUTT-3= and 5=-GAGGAACAUGCUGUUUGUATT-3=) and human CXXC5 (NP_057547; 5=-CUCAGUGGCAGAU-GACA-CATT-3= and 5=-GCACCCGUCUUUAGAACCATT-3=) were synthesized (Bioneer) for knockdown of CXXC5. A GFP siRNA (5=-GCAUCAAGGUGAACUUCAATT-3=; Bioneer) was used as a negative control. siRNAs were transfected into mESCs and HUVECs at a concentration of 100 nM in a 6-well culture plate using the Lipofectamine Plus reagent (Invitrogen). Transfected cells were further cultured for 36 or 72 h before harvest for RT-PCR analysis or tube formation assay.
In vitro tube formation
Growth Factor Reduced Matrigel Matrix (250 l; BD Biosciences) was added to each well of a 24-well culture plate and allowed to solidify at 37°C for Ն30 min. mESCs at 4 d of differentiation (7ϫ10 4 ) and HUVECs (3ϫ10 4 ) were then seeded on the Matrigel-coated wells, cultured at 37°C in a 5% CO 2 atmosphere incubator for 8ϳ24 h, and observed with a light microscope (Eclipse TE2000-U; Nikon, Tokyo, Japan) equipped with a digital CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA) to verify the formation of the capillary-like structures.
Wound healing assay and immunocytochemical analysis
For immunocytochemistry, mESCs and HUVECs were plated on 0.1% gelatin or mouse collagen IV-coated glass coverslips at a density of 0.5ϳ0.7 ϫ 10 5 cells/well in a 24-well culture plate. For wound healing assay, a wound was made by scratching the glass using a pipette tip. mESCs were washed with PBS and fixed in 4% paraformaldehyde (PFA) for 30 min at room temperature. Then, cells were washed 3 times with PBS and rendered permeable with 0.1% Triton X-100 in PBS for 30 min. After being washed 3 times with PBS, the cells were incubated with blocking solution (1% BSA and 1% normal goat serum in PBS) for 30 min and incubated with anti-Oct-4, anti-Flk-1, cleaved poly-ADP-ribose polymerase (PARP; Cell Signaling), or anti-CXXC5 antibody in blocking solution at 4°C overnight. Next, the cells were washed 3 times in PBS and incubated with Alexa Fluor 488-conjugated anti-rabbit IgG or Alexa Fluor 555-conjugated anti-mouse IgG secondary antibody (Invitrogen) at room temperature for 1 h. For cytoskeleton visualization, FITC-conjugated phalloidin (Invitrogen) was treated with the secondary antibodies. Cell nuclei were counterstained by incubating cells in 1 g/ml DAPI (Boehringer Mannheim, Indianapolis, IN, USA) for 10 min and were then washed extensively in distilled water. Samples that were fluorescently labeled were examined with a Radiance 2100 multiphoton imaging system (Bio-Rad Laboratories) and a LSM510 Meta microscope (Carl Zeiss, Jena, Germany). The number of cells in wounding area was counted as described previously (28) .
Zebrafish experiments
Zebrafish embryos were raised and maintained using standard procedures, and developmental stages were determined as described previously (29) . At 24 h postfertilization (hpf), embryos were transferred to water with 0.003% 1-phenyl-2-thiourea (PTU; Sigma) to inhibit pigment formation. The zebrafish lines used in the study were wild-type and Tg(kdrl: EGFP) s843 (30) . Morpholino oligonucleotides (MOs) for cxxc5 (cxxc5 MOs; 5=-GCTGTCCGCCAGACATGGTCCAGCC-3=) and control MOs (5=-CCTCTTACCTCAGTTACAATTTATA-3=) were purchased from Gene Tools (Corvallis, OR, USA). The MOs were dissolved in 1ϫ Danieau solution at a concentration of 10 mM and were further diluted with distilled water. Morpholino oligonucleotide (10 ng) was injected into 1-to 2-cell-stage embryos. Zebrafish embryos were cleansed and dissected in PBS. Isolated embryos and tissues were fixed in 4% PFA in PBS supplemented with 4% sucrose overnight at 4°C. For whole-mount embryo staining, embryos were washed in 0.8% TritonX-100 in PBS (PBST), transferred to PBST containing methanol, and then stored Ϫ20°C until staining. The embryos were permeablized in 1 mg/ml proteinase K in PBST at 25°C for 40 min. The permeabilization was stopped by being washed with PBST, and then the free amines were quenched with 1 M glycine (pH 8.0). Postfixation were done using 4% PFA in PBS for 20 min at room temperature. Blocking was performed using PBST containing 10% goat serum and 1% DMSO for 2 h at room temperature, and then the embryos were incubated with anti-Flk-1 and anti-cleaved caspase 3 (Cell Signaling) antibodies overnight at 4°C. After being washed with PBST, the embryos were incubated with Alexa Fluor 488-conjugated anti-goat IgG and Alexa Fluor 488-conjugated anti-rat IgG overnight at 4°C. The embryos were washed with PBST and then transferred into PBS containing glycerol for visualization. Immunofluorescent images were visualized using an Eclipse TE2000-U fluorescent microscope. For paraffin sectioning, tissues were dehydrated by serial immersion in ethanol, cleared in xylene, and embedded in paraffin. Tissue blocks were sectioned as 4-m slices using a microtome. Paraffin-preserved tissues were stored at room temperature before sectioning. Sectioned slices were blocked with serum-free protein blocker (Dako, High Wycombe, UK) and stained with anti-CXXC5, anticleaved caspase 3, or anti-Flk-1 (BD PharMingen, San Diego, CA, USA) antibody. Alexa Fluor 488-conjugated anti-goat IgG and Alexa Fluor 488-conjugated anti-rat IgG were used as the secondary antibodies. The slices were counterstained with DAPI. Confocal images were obtained using with a Radiance 2100 multiphoton imaging system and a LSM510 Meta microscope. The thickness of PCV of control MO-injected and cxxc5 MO-injected Tg(flk-1:EGFP) zebrafish embryo at 50 hpf was measured from fluorescent microscope images using NISElements software (Nikon). The percentage of ISA-or CVPcontaining segments was calculated from control MOinjected and CXXC5 MO-injected Tg(flk-1:EGFP) zebrafish embryos at 50 hpf, as described previously (13) .
In vivo angiogenesis analysis
The angiogenesis analysis was performed using the Matrigel implant model system in CXXC5 ϩ/ϩ and CXXC5 Ϫ/Ϫ mice, as described previously (31) . Growth factor-reduced Matrigel (BD Biosciences) was thawed overnight on ice and mixed with 1 g/ml BMP4 in combination with noggin. Matrigel (500 l) was injected subcutaneously into the dorsal surfaces of CXXC5 ϩ/ϩ and CXXC5 Ϫ/Ϫ mice aged 2.5ϳ3.5 mo. After 14 d, the Matrigel plugs were isolated and fixed in 4% paraformaldehyde/PBS overnight at 4°C. For cryopreservation, implanted Matrigels were immersed through a graded saccharose/PBS series and then were embedded in Tissue-Tek optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA). Cryopreserved tissues were stored at Ϫ80°C until sectioning. Sectioned slices were blocked with serum-free protein blocker and stained with anti-CXXC5, anti-cleaved PARP, or anti-PECAM-1 (BD Biosciences) antibody. Alexa Fluor 488-conjugated anti-goat IgG and Alexa Fluor 488-conjugated anti-rat IgG were used as the secondary antibodies. The slices were counterstained with DAPI. Immunofluorescent images were visualized using a Radiance 2100 multiphoton imaging system and a LSM510 Meta microscope.
RESULTS

CXXC5 is induced during the endothelial differentiation of mESCs and stimulates Flk-1 transcription in differentiated mESCs and HUVECs
To characterize the involvement of CXXC5 in the endothelial differentiation of mESCs, the mRNA and protein levels of CXXC5 were measured during the differentiation process. The mRNA levels of CXXC5 were increased significantly, along with those of Flk-1, Flt-1, and Tie-2 by endothelial differentiation of mESCs (Fig. 1A) . The protein level of CXXC5 was also increased, whereas that of Oct-4, an ESC marker, was decreased following mESC differentiation (Fig. 1B) . The increases in both CXXC5 and Flk-1 during mESC endothelial differentiation were further confirmed by immunocytochemical analyses. Here, CXXC5 and Flk-1 protein levels were significantly increased and localized to the nucleus and membrane, respectively, in differentiated mESCs (Fig. 1C, bottom panels) . To investigate the role of CXXC5 in the endothelial differentiation of mESCs, CXXC5 was transfected, and the mRNA levels of endothelial differentiation markers were monitored in undifferentiated and differentiated mESCs. Following CXXC5 transfection, the mRNA levels of Flk-1 increased significantly in differentiated mESCs (Fig.  1D, E) . However, the induction of Flk-1 mRNAs by CXXC5 transfection was not observed in undifferentiated mESCs (Fig. 1D) . In addition, Tie-2 mRNA was induced in differentiated mESCs but was not further increased by CXXC5 transfection (Fig. 1D) , indicating that CXXC5 specifically induce Flk-1 transcription. The transcriptional induction of Flk-1 by CXXC5 transfection was further confirmed by reporter analyses, in which Flk-1 promoter activity was dose-dependently and significantly increased by CXXC5 transfection in differ-entiated, but not undifferentiated, mESCs (Fig. 1F) . As expected, the mRNA level of Flk-1 was reduced by CXXC5 knockdown in differentiated mESCs (Fig. 1G) . Moreover, the level of Flk-1 mRNA was also increased and decreased as a result of CXXC5 overexpression and knockdown, respectively, in HUVECs (Supplemental Fig. S1A, B) . The induction of Flk-1 expression by CXXC5 was also demonstrated by the increased Flk-1 protein level in HUVECs transfected with CXXC5 (Supplemental Fig. S1C ). However, Flk-1 mRNA was not altered as a result of transfection with CXXC4, an analog of CXXC5, in HUVECs (Supplemental Fig. S1D ), indicating that the transcriptional induction of Flk-1 in endothelial cells was CXXC5 specific.
CXXC5 is a nuclear transcription factor that induces
Flk-1 expression during the endothelial differentiation of mESCs
The CXXC5 induced during the endothelial differentiation of mESCs was localized primarily within the nucleus (Fig. 1C) , and the nuclear localization and accumulation of CXXC5 in differentiated mESCs were confirmed by cell fractionation assays (Fig. 2A) . The ␤-catenin level was not reduced by CXXC5 transfection in either mESCs or HUVECs (Fig. 2B and Supplemental Fig. S1C) , and the mRNA levels of c-Myc and cyclinD1, both well-known target genes of Wnt/␤-catenin pathway (32, 33) , also did not decrease on CXXC5 transfection in differentiated mESCs (Fig. 1E) . These results imply that CXXC5 functions as a nuclear factor rather than a cytosolic negative regulator of Wnt/␤-catenin signaling in endothelial cells.
To identify the functional domains in CXXC5 mediating Flk-1 regulation, N-terminal and C-terminal deletion mutants, CXXC5 (⌬1-249) and CXXC5 (⌬250 -322), were generated (Fig. 2C) , and the effects of these mutants on the expression of Flk-1 mRNA were examined. the Flk-1 mRNA level increased on transfection of the CXXC5 (⌬1-249) mutant in endothelial-differentiatied mESCs (Fig. 2D) . However, transfection of CXXC5 (⌬250 -322), which lacks the putative CXXC DNAbinding domains (34, 35) , did not increase Flk-1 mRNA (Fig. 2E) . The loss of function of CXXC5 (⌬250ϳ322) was confirmed by Flk-1 reporter analyses (Fig. 2F) . Moreover, both the mRNA level and reporter activity of Flk-1 decreased on CXXC5 (⌬250 -322) transfection (Fig. 2E, F) . To further confirm the role of the CXXC domains of CXXC5 in Flk-1 expression, we generated point mutants in which the Cys-263/266 and Cys-275/ 278 residues were replaced with arginine residues in the first and second CXXC domains, respectively (Fig.  2C) . Both the mRNA level and promoter activity of Flk-1 were decreased following transfection with CXXC5 (C263/266R), as similar with CXXC5 (⌬250 -322) trans- fection, in differentiated mESCs (Fig. 2G, H) . However, transfection with the CXXC5 (C275/278R) mutant increased the level of Flk-1 mRNA in differentiated mESCs (Fig. 2I) and also increased Flk-1 mRNA to wild-type levels in comparison with control in HUVECs (Fig. 2J) . We further confirmed the reduced, rather than increased, Flk-1 transcription following CXXC5 (C263/266R) transfection in HUVECs (Fig. 2J) . These results indicated that CXXC5 (C263/266R) and CXXC5 (⌬250 -322) acted as dominant-negative mutants in terms of their effect on the transcriptional activation of Flk-1.
To further confirm the role of CXXC5 as a transcription factor for Flk-1, in vitro DNA binding assays were performed with purified recombinant CXXC5 and Flk-1 promoter fragments. CXXC5 interacted with Flk-1 promoter fragments spanning the Ϫ629-to Ϫ1-bp region from the transcription start site, as shown by electrophoretic mobility shift assay (EMSA; Fig. 2K) . Moreover, the specificity of the interaction between CXXC5 and the Flk-1 promoter DNA fragments was confirmed by the competition of CXXC5-Flk-1 fragment binding with an unlabeled cold DNA probe and a supershift of the DNAprotein complex with an anti-CXXC5 antibody (Fig. 2K) . Thus, the first CXXC domain (34, 35) is essential for the role of CXXC5 as a transcriptional activator for Flk-1.
CXXC5 mediates the transcriptional induction of
Flk-1 via BMP4-Smad signaling
BMP4-Smad signaling has been shown to be involved in the differentiation of human ESCs into vascular progenitor cells (36) . We found that BMP4 induced both Flk-1 and CXXC5 mRNAs in HUVECs (Fig. 3A and Supplemental Fig. S1E ). Smad1/5/8 are phosphorylated by BMP-activated receptors to bind with Smad4 -1, hCXXC5 , hGAPDH, and HPRT, or were subjected to Flk-1 promoter reporter analyses (F, H). Error bars ϭ sd of 3 independent analyses. *P Ͻ 0.05, **P Ͻ 0.01. K) EMSA using Flk-1 promoter fragments spanning the Ϫ629-to Ϫ1-bp region from the transcription start site and recombinant CXXC5 including cold-DNA probe competition and supershift assays using an anti-CXXC5 antibody.
and translocate into the nucleus to induce target genes (37) . With the increase in phosphorylated Smad1/5/8 (p-Smad1/5/8), the protein levels of both Flk-1 and CXXC5 were time dependently increased by BMP4 treatment in HUVECs (Fig. 3B) . Despite a slight increase in the mRNA level of Flk-1, that of CXXC5 was not altered by Wnt3a treatment (Supplemental Fig.  S1E ). In contrast to the effect of BMP4, treatment with TGF-␤, another protein from same family, reduced the mRNA level of Flk-1 in HUVECs and differentiated mESCs (Supplemental Fig. S1F, G) , indicating the specificity of BMP4 for the induction of Flk-1 mRNA.
The basal level of Flk-1 mRNA was reduced following treatment with noggin, a BMP4 antagonist, and DM, a selective chemical inhibitor of BMP signaling, in HUVECs (Fig. 3C, D) . Flk-1 mRNA induction following endothelial differentiation of mESCs was also dose dependently inhibited by noggin and DM (Supplemental Fig. S1H, I) . Furthermore, the BMP4-induced increase in Flk-1 mRNA was also blocked by treatment with noggin or DM in HUVECs (Fig. 3E, F) . Interestingly, the induction of CXXC5 mRNA by BMP4 was also significantly reduced following treatment with these inhibitors (Fig. 3E, F) . Down-regulation of the protein level of Flk-1 with p-Smad1/5/8 following DM treatment was also confirmed in HUVECs and differentiated mESCs ( Fig. 3G and Supplemental Fig. S1J ). The BMP4-induced Flk-1 mRNA increase was blocked by CXXC5 siRNA transfection in HUVECs (Fig. 3H) , indicating that CXXC5 is a key factor for Flk-1 mRNA induction by BMP4. To further confirm that CXXC5 functions downstream of the BMP4 signal to induce Flk-1 transcription, we tested the effect of CXXC5 overexpression in cells treated with noggin or DM. In these HUVECs, CXXC5 induced Flk-1 mRNA regardless of pretreatment with noggin or DM (Fig. 3I, J) . In addition, the Flk-1 mRNA induction by CXXC5 was not affected by noggin or DM in differentiated mESCs ( 3K, L). However, Flk-1 mRNA induction by BMP4 was reduced following overexpression of a dominant-negative mutant, CXXC5 (C263/266R), in HUVECs (Fig.  3M) . Overexpression of inhibitory Smads, Smad6 and Smad7 (38) , reduced Flk-1 mRNA level in both differentiated mESCs and HUVECs (Supplemental Fig S1K,  L) . These results indicate that CXXC5 functions downstream of BMP4 signaling to mediate BMP4-induced transcriptional activation of Flk-1 in endothelial cells and endothelium-differentiated mESCs.
CXXC5 plays a role in BMP4-induced motility and tube formation in endothelial cells
BMP2 treatment or overexpression of BMP endothelial cell precursor-derived regulator (BMPER), an agonist of BMP4, has been shown to induce stress fiber formation and cell motility (39, 40) . We found that BMP4 treatment also increased the number of cells forming stress fibers in HUVECs (Fig. 4A, B and Supplemental  Fig. S2A ). Transfection of CXXC5 siRNA reduced the number of stress fiber-forming cells to below the basal level, regardless of BMP4 treatment (Fig. 4B) . In addition, the numbers of migrated cells increased following BMP4 treatment, and the number also decreased on CXXC5 knockdown (Fig. 4C, D and Supplemental Fig.  S2B ). Interestingly, CXXC5 was highly expressed in cells showing high mobility (Supplemental Fig. S2B) .
To characterize the role of CXXC5 in vascularization, the effects of CXXC5 on the formation of tube-like structures were investigated. Total capillary length and the number of tube-like structures in both differentiated mESCs and HUVECs on Matrigel increased on CXXC5 transfection (Fig. 4E-G) . In contrast, the total capillary length and number of tube-like structures of these cells decreased following the transfection of CXXC5 siRNA (Fig. 4E-G) . Furthermore, overexpres- Effects of CXXC5 on BMP4-induced stress fiber formation and cell migration, and Matrigel-induced tube formation in HUVECs or mESCs. A) HUVECs were transfected with 100 nM GFP or CXXC5 siRNA and then treated with 20 ng/ml BMP4 in serum-free conditions for 16 h. CXXC5 was detected by immunocytochemical analysis using a CXXC5 antibody (red). Cytoskeletons were visualized using FITC-conjugated phalloidin (green). Nuclei were counterstained with DAPI (blue). Scale bar ϭ 25 m. B) Percentage of cells from panel A forming stress fiber. C) HUVECs were transfected with 100 nM GFP or CXXC5 siRNA. Wounds were made as described previously (28) , and the cells were then treated with 20 ng/ml BMP4 in serum-free conditions for 16 h. Immunocytochemical analysis was performed as described in panel A. Scale bar ϭ 100 m. D) Number of cells in the wounded area from panel C. E-H) mESCs and HUVECs were transferred onto Matrigel-coated plates and transfected with 100 nM GFP or CXXC5 siRNA, or pcDNA3.1, Myc-CXXC5-pcDNA3.1, Myc-CXXC5(C263/266R)-pcDNA3.1, or Myc-CXXC5(C275/278R)-pcDNA3.1. Tube formation was observed after 24 h. Scale bars ϭ 200 m. Capillary length (F) and numbers of tube-like structures (G) were calculated as described previously (46, 47) . Error bars ϭ sd of 3 independent reporter analyses. *P Ͻ 0.05, **P Ͻ 0.01. sion of CXXC5 (C263/266R), a dominant-negative mutant, reduced the formation of vascular-like structures, whereas overexpression of CXXC5 or CXXC5 (C275/278R) increased this formation (Fig. 4H) . These results indicate that CXXC5 mediates BMP4-induced cell motility and in vitro tube formation of endothelial cells.
CXXC5 is required for axial vein angiogenesis during zebrafish development
BMP signaling mediates sprouting angiogenesis from the PCV to form the CVP during early vascular development in zebrafish (13) . The inhibition of BMP signaling in early zebrafish embryos results in aberrant CVP formation; the dorsal aorta (DA) and the caudal vein (CV) are incompletely separated, and the number of fused ventral vein (VV) decrease without any effect on ISA formation (13) . cxxc5 was specifically expressed in the PCV region of zebrafish embryo at 50 hpf, as confirmed by immunofluorescent labeling of the sagittal, transverse, and coronal sections of Tg(flk-1:EGFP) zebrafish embryos ( Fig. 5A and Supplemental Fig. S3A , arrows). The immunofluorescence was abolished by preblocking of the sections with purified CXXC5, which confirms the specificity of anti-CXXC5 antibody (Supplemental Fig. S3B ). The Tg(flk-1:EGFP) embryos at 50 hpf that were injected with cxxc5 morpholinos demonstrated downward-curved body phenotypes (Fig. 5B) and aberrant PCV and CVP formation (Fig. 5C ). The thickness of the PCV was reduced in embryos injected with cxxc5 morpholinos compared with those injected with control morpholinos (Fig. 5C , middle panels; D; and Supplemental Fig. S3C ). The DA and CV separation was incomplete, and the number of fused VVs was decreased in the CVP region of embryos injected with cxxc5 morpholinos ( (13) . F, G) Control MO-injected and CXXC5 MO injected Tg(flk-1:EGFP) zebrafish embryos at 50 hpf were subjected to whole-mount immunohistochemical analyses to visualize cleaved caspase 3 (F). Scale bar ϭ100 m. Numbers of cleaved caspase 3-positive puncta were counted. Error bars ϭ sd of 3 independent reporter analyses (G). *P Ͻ 0.05. 5C, bottom panels; E; and Supplemental Fig. S3D ). However, the number of ISAs that reached the dorsal longitudinal anastomotic vessel was not altered in the cxxc5 morpholino-injected embryos (Fig. 5C , E and Supplemental Fig. S3D ). In addition, cxxc5 morpholinoinjected Tg(flk-1:EGFP) embryos at 36 hpf showed axial vein-specific induction of endothelial cell apoptosis, as revealed by cleaved caspase 3 staining (Fig. 5F , G and Supplemental Fig. S3E ). In HUVECs, CXXC5 knockdown also increased the number of apoptotic bodies, which were shown by high accumulation of cleaved PARP, a marker of cells undergoing apoptosis (ref. 41 and Supplemental Fig. S3F ). Thus, CXXC5 is involved in BMP-specific PCV and CVP formation during early zebrafish development.
CXXC5 is required for BMP4-induced angiogenesis in vivo
To further characterize the role of CXXC5 in angiogenesis induced by BMP4 in vivo, we performed the Matrigel plug assay in CXXC5 ϩ/ϩ and CXXC5 Ϫ/Ϫ mice. Matrigel mixed with BMP4 with or without noggin was injected subcutaneously into CXXC5 ϩ/ϩ and CXXC5 Ϫ/Ϫ mice. The blood vessels were monitored at d 14 after injection.
Microvessel formation in the Matrigel plugs was significantly enhanced by BMP4 treatment in CXXC5 ϩ/ϩ mice (Supplemental Fig. S4A , right panels show enlarged images of vessels in the plugs). Hematoxylin and eosin staining of the plug sections revealed tube structure of vessels clearly, in which red blood cells were visualized by eosin staining (Supplemental Fig. S4B, C) . However, BMP4-induced microvessel formation in the Matrigel plugs was abolished in CXXC5 Ϫ/Ϫ mice (Supplemental Fig. S4A ). Furthermore in CXXC5 Ϫ/Ϫ mice, cleaved PARP was increased in the cells migrated into the Matrigel plugs (Supplemental Fig. S4D ). Immunohistochemical staining of platelet endothelial cell adhesion molecule (PECAM-1), an endothelial cell surface marker (42) , more clearly demonstrated BMP4-induced microvessel formation and the absence of this effect in CXXC5 Ϫ/Ϫ mice (Fig. 6A) . Furthermore, the presence of noggin or DM inhibited the formation of blood vessels induced by BMP4 in CXXC5 ϩ/ϩ mice, as shown by a significant reduction in PECAM-1 staining (Fig. 6B and Supplemental Fig. S4E ). Similar to the results of our in vitro analyses, CXXC5 was also induced by BMP4 in the Matrigel plug in CXXC5 ϩ/ϩ mice but not CXXC5 Ϫ/Ϫ mice, and this BMP4 effect in CXXC5 ϩ/ϩ mice was blocked by noggin (Supplemental and CXXC5 Ϫ/Ϫ mice and harvested at d 14 after implantation. Matrigel plugs were subjected to immunohistochemical analyses with an anti-PECAM-1 antibody (green) to observe vascular structures. Nuclei were counterstained with DAPI (blue). Scale bars ϭ 100 m. Fig. S4F ). Thus, CXXC5 is an essential factor for BMP4-induced angiogenesis in mice.
DISCUSSION
Genetic and functional studies have highlighted BMP signaling as a critical pathway regulating endothelial differentiation and vascular development and homeostasis (6) . We found that the mRNA level of Flk-1 increased on treatment with BMP4 or Wnt3a, whereas that of CXXC5 was increased only by BMP4 treatment, indicating that CXXC5 induction was specific to BMP signaling. Moreover, the BMP4-induced Flk-1 increment was blocked by BMP signaling inhibitors or CXXC5 knockdown, while Flk-1 increment induced by CXXC5 overexpression was not inhibited by the BMP signaling inhibitors. These results indicate that CXXC5 functions downstream of BMP signaling.
In this study, we characterized CXXC5 as a transcription factor for Flk-1 and a mediator of endothelial differentiation by BMP4. First, CXXC5 was found in the nucleus but not in the cytoplasm of mESCs differentiating into endothelial cells. Second, mRNA and promoter activity of Flk-1 were increased by overexpression of CXXC5 but not by the overexpression of its mutants lacking DNA-binding motif. Furthermore, CXXC5-Flk-1 promoter interaction was confirmed by DNA binding analyses. We also found that ␤-catenin levels were not changed by CXXC5 overexpression in HUVECs or mESCs. Overall, CXXC5 is a transcription factor that binds to the Flk-1 promoter and induces Flk-1 expression in HUVECs and endothelial-differentiated mESCs.
The BMP signaling stimulates cell migration and tube formation in endothelial cells (43) , and we confirmed the roles of CXXC5 in these functions. We further highlighted roles for CXXC5 in cytoskeletal rearrangement and cell migration mediated by BMP4 in endothelial cells. The migration of endothelial cells is essential for sprouting angiogenesis, a complex process involving the sprouting of capillaries from preexisting parent vessels, and the proliferation, migration, and fusion of endothelial cells participating in sprouting angiogenesis are tightly regulated by numerous and specific signals during vessel structure formation (44) . In early zebrafish development, sprouting angiogenesis from the DA and PCV are spatiotemporally closed events (45) . However, a recent study showed that ISA formation via DA sprouting and CVP formation via PCV sprouting are specifically activated by VEGF-A and BMP, respectively (13) . We found that CXXC5 is specifically expressed in the PCV region of early zebrafish embryos. cxxc5 knockdown in zebrafish embryo resulted in an aberrant CVP formation but no defects in ISA formation, which mimics the phenotypes previously obtained by the inhibition of BMP signaling in zebrafish embryos (13) .
During the sprouting angiogenesis, angiogenic endothelial cells degrade the extracellular matrix to enable their migration and have a high susceptibility to anoikis (45) . As a result, these endothelial cells are easily driven to apoptosis when they deviate from the correct location and lose cell survival signals from their surroundings (45) . cxxc5 MO-injected zebrafish embryos showed PCV-specific induction of endothelial cell apoptosis, which may have been caused by inhibition of BMP-induced endothelial cell migration. The role of CXXC5 in angiogenesis was also confirmed by loss of BMP4-induced vessel-like structure formation and the increase of apoptotic cells in the Matrigel plug transplanted into CXXC5 Ϫ/Ϫ mice. This evidence demonstrates that CXXC5 acts as a mediator of BMP4-induced in vivo endothelial migration and differentiation and angiogenesis.
In summary, we identified CXXC5 as a transcriptional factor activating Flk-1, involved in BMP-induced endothelial differentiation. We also characterized CXXC5 as an essential factor mediating BMP-related vessel development in zebrafish.
